T2 Biosystems Incの将来のP / E
T2 Biosystems Incの将来のP / Eは何ですか。
T2 Biosystems Incの将来のP / Eは-1.64です。
将来のP / Eの定義は何ですか。
未来比率P / E (株価収益率)は、企業の株価と今後12ヶ月間の1株当たり利益見込額との比率です。
The forward price to earnings ratio is similar to trailing price to earnings ratio but instead of net income uses estimated net earnings over next 12 months. Estimates are typically derived as the mean of those published by a select group of analysts with selection criteria varying. The forward price-to-earnings ratio is a powerful, but limited tool. It allows a quick snapshot of the company’s finances without getting down in the details of an accounting report.
NASDAQのセクタHealth Careにおける将来のP / Eの企業と比べるT2 Biosystems Inc
T2 Biosystems Incは何をしますか。
t2 biosystems is developing innovative diagnostic products to improve patient health. with two fda-cleared products targeting sepsis – the cause of one out of two hospital deaths - and a range of additional products in development, t2 biosystems is an emerging leader in the field of in vitro diagnostics. our initial development efforts target sepsis, hemostasis, bacteria and lyme disease, which are areas of significant unmet medical need. the company is utilizing its proprietary t2 magnetic resonance platform, or t2mr®, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. at t2 biosystems, we know that our passion to advance the medical diagnostic landscape relies on our ability to attract and retain the very best people in the world – and to encourage them to flourish. we invite you to apply for one of our open positions at www
T2 Biosystems Incと類似の将来のp / e
- Tiziana Life Sciences Ltdの将来のP / Eは-1.76です。
- Allogene Therapeutics Incの将来のP / Eは-1.74です。
- Applied Dna Sciences Incの将来のP / Eは-1.72です。
- Resaas Servicesの将来のP / Eは-1.70です。
- Contact Goldの将来のP / Eは-1.67です。
- FAT Brands Incの将来のP / Eは-1.66です。
- T2 Biosystems Incの将来のP / Eは-1.64です。
- Cotinga Pharmaceuticalsの将来のP / Eは-1.63です。
- Osmotica Pharmaceuticals Plcの将来のP / Eは-1.61です。
- Black Diamond Therapeutics Incの将来のP / Eは-1.59です。
- Proteostasis Therapeutics Incの将来のP / Eは-1.57です。
- Hepion Pharmaceuticals Incの将来のP / Eは-1.56です。
- Suzlonの将来のP / Eは-1.53です。